{
  "resourceType" : "ValueSet",
  "id" : "2.16.840.1.113883.3.7643.3.1009",
  "meta" : {
    "versionId" : "6",
    "lastUpdated" : "2019-01-08T01:00:08.000-05:00",
    "profile" : ["http://hl7.org/fhir/StructureDefinition/shareablevalueset",
    "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"]
  },
  "extension" : [{
    "url" : "http://hl7.org/fhir/StructureDefinition/valueset-author",
    "valueString" : "Oncology Nursing Society Author"
  },
  {
    "url" : "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
    "valueDate" : "2022-12-15"
  },
  {
    "url" : "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
    "valueDate" : "2019-01-08"
  }],
  "url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.7643.3.1009",
  "identifier" : [{
    "system" : "urn:ietf:rfc:3986",
    "value" : "urn:oid:2.16.840.1.113883.3.7643.3.1009"
  }],
  "version" : "20190108",
  "name" : "CheckpointInhibitorsWithPotentialToCauseGrade3OrHigherFatigue",
  "title" : "Checkpoint Inhibitors with Potential to Cause Grade 3 or Higher Fatigue",
  "status" : "active",
  "experimental" : false,
  "date" : "2019-01-08T01:00:08-05:00",
  "publisher" : "Oncology Nursing Society Steward",
  "jurisdiction" : [{
    "extension" : [{
      "url" : "http://hl7.org/fhir/StructureDefinition/data-absent-reason",
      "valueString" : "UNKNOWN"
    }]
  }],
  "purpose" : "(Clinical Focus: This value set contains RxNORM concepts for various checkpoint inhibitor agents, regardless of dosage or administration route.),(Data Element Scope: Various drugs used in the treatment of cancer which may cause fatigue.),(Inclusion Criteria: atezolizumab, avelumab, durvalumab, ipilimumab, nivolumab, pembrolizumab),(Exclusion Criteria: Brand name drugs and drug packs. Chemotherapy and biotherapy agents which may cause fatigue.)",
  "compose" : {
    "include" : [{
      "valueSet" : ["http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.7643.2.1006"]
    }]
  },
  "expansion" : {
    "identifier" : "urn:uuid:70163b90-cbdd-498f-8dd2-2835ed7236ec",
    "timestamp" : "2023-09-26T09:17:50-04:00",
    "total" : 11,
    "offset" : 0,
    "parameter" : [{
      "name" : "count",
      "valueInteger" : 1000
    },
    {
      "name" : "offset",
      "valueInteger" : 0
    }],
    "contains" : [{
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "version" : "09052023",
      "code" : "1657005",
      "display" : "40 ML ipilimumab 5 MG/ML Injection"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "version" : "09052023",
      "code" : "1657012",
      "display" : "10 ML ipilimumab 5 MG/ML Injection"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "version" : "09052023",
      "code" : "1657190",
      "display" : "4 ML nivolumab 10 MG/ML Injection"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "version" : "09052023",
      "code" : "1657195",
      "display" : "10 ML nivolumab 10 MG/ML Injection"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "version" : "09052023",
      "code" : "1657746",
      "display" : "pembrolizumab 50 MG Injection"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "version" : "09052023",
      "code" : "1657750",
      "display" : "4 ML pembrolizumab 25 MG/ML Injection"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "version" : "09052023",
      "code" : "1792780",
      "display" : "20 ML atezolizumab 60 MG/ML Injection"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "version" : "09052023",
      "code" : "1875542",
      "display" : "10 ML avelumab 20 MG/ML Injection"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "version" : "09052023",
      "code" : "1919507",
      "display" : "2.4 ML durvalumab 50 MG/ML Injection"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "version" : "09052023",
      "code" : "1919515",
      "display" : "10 ML durvalumab 50 MG/ML Injection"
    },
    {
      "system" : "http://www.nlm.nih.gov/research/umls/rxnorm",
      "version" : "09052023",
      "code" : "1991412",
      "display" : "24 ML nivolumab 10 MG/ML Injection"
    }]
  }
}